Involvement	O
of	O
PTEN	O
promoter	O
methylation	O
in	O
cerebral	B-Pathological_formation
cavernous	I-Pathological_formation
malformations	I-Pathological_formation
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	B-Pathological_formation
cavernous	I-Pathological_formation
malformations	I-Pathological_formation
(	O
CCMs	B-Pathological_formation
)	O
are	O
prevalent	O
cerebral	B-Pathological_formation
vascular	I-Pathological_formation
lesions	I-Pathological_formation
involving	O
aberrant	O
angiogenesis	O
.	O

However	O
,	O
the	O
underlying	O
mechanism	O
is	O
poorly	O
understood	O
.	O

Phosphatase	O
and	O
tension	O
homolog	O
deleted	O
on	O
chromosome	O
10	O
(	O
PTEN	O
)	O
,	O
a	O
tumor	B-Cancer
suppressor	O
,	O
is	O
frequently	O
deficient	O
in	O
various	O
pathologies	O
due	O
to	O
mutation	O
or	O
epigenetic	O
alterations	O
.	O

PTEN	O
promoter	O
hypermethylation	O
is	O
a	O
major	O
epigenetic	O
silencing	O
mechanism	O
leading	O
to	O
activation	O
of	O
angiogenesis	O
in	O
tumors	B-Cancer
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
whether	O
PTEN	O
promoter	O
methylation	O
was	O
involved	O
in	O
CCMs	B-Pathological_formation
.	O

METHODS	O
:	O
PTEN	O
promoter	O
methylation	O
was	O
detected	O
in	O
surgical	B-Pathological_formation
specimens	I-Pathological_formation
of	O
CCMs	B-Pathological_formation
(	O
n	O
=	O
69	O
)	O
by	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O

The	O
methylation	O
status	O
was	O
correlated	O
to	O
the	O
clinical	O
manifestations	O
and	O
to	O
PTEN	O
expression	O
,	O
which	O
was	O
analyzed	O
by	O
both	O
Western	O
blot	O
and	O
immunohistochemistry	O
.	O

To	O
investigate	O
the	O
endothelial	B-Cell
proliferation	O
and	O
the	O
potential	O
signaling	O
pathways	O
affected	O
by	O
PTEN	O
methylation	O
,	O
proliferating	O
cell	O
nuclear	O
antigen	O
as	O
well	O
as	O
phosphor	O
-	O
Akt	O
and	O
phosphor	O
-	O
Erk1	O
,	O
2	O
were	O
detected	O
by	O
immunofluorescence	O
and	O
Western	O
blot	O
,	O
respectively	O
,	O
in	O
CCM	B-Pathological_formation
specimens	I-Pathological_formation
.	O

RESULTS	O
:	O
Methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
revealed	O
PTEN	O
promoter	O
methylation	O
in	O
15	O
.	O
9	O
%	O
CCMs	B-Pathological_formation
.	O

Strikingly	O
,	O
5	O
of	O
6	O
familial	O
CCMs	B-Pathological_formation
showed	O
PTEN	O
promoter	O
methylation	O
(	O
83	O
.	O
3	O
%	O
)	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
in	O
sporadic	O
cases	O
(	O
9	O
.	O
4	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
addition	O
,	O
PTEN	O
promoter	O
methylation	O
appeared	O
more	O
frequently	O
in	O
multiple	O
CCMs	B-Pathological_formation
,	O
including	O
familial	O
cases	O
(	O
46	O
.	O
7	O
%	O
)	O
,	O
than	O
that	O
in	O
single	O
-	O
lesioned	O
CCMs	B-Pathological_formation
(	O
11	O
.	O
8	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Immunostaining	O
and	O
Western	O
blot	O
revealed	O
a	O
more	O
significant	O
PTEN	O
downregulation	O
in	O
PTEN	O
-	O
methylated	O
CCMs	B-Pathological_formation
in	O
comparison	O
to	O
PTEN	O
-	O
unmethylated	O
CCMs	B-Pathological_formation
.	O

Reduced	O
PTEN	O
expression	O
was	O
inversely	O
correlated	O
to	O
the	O
expression	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
and	O
to	O
the	O
activation	O
of	O
Erk1	O
,	O
2	O
,	O
but	O
not	O
of	O
Akt	O
.	O

CONCLUSIONS	O
:	O
We	O
reported	O
here	O
for	O
the	O
first	O
time	O
the	O
involvement	O
of	O
PTEN	O
promoter	O
methylation	O
in	O
CCMs	B-Pathological_formation
,	O
particularly	O
in	O
familial	O
CCMs	B-Pathological_formation
,	O
suggesting	O
this	O
epigenetic	O
alteration	O
as	O
a	O
potential	O
pathomechanism	O
of	O
CCMs	B-Pathological_formation
.	O

The	O
identification	O
of	O
Erk1	O
,	O
2	O
as	O
triggered	O
signaling	O
in	O
the	O
lesions	B-Pathological_formation
may	O
be	O
valuable	O
for	O
the	O
development	O
of	O
effective	O
therapy	O
for	O
this	O
disease	O
.	O

